<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03526510</url>
  </required_header>
  <id_info>
    <org_study_id>pHART2 RCT</org_study_id>
    <nct_id>NCT03526510</nct_id>
  </id_info>
  <brief_title>Hypofractionated Boost vs Conventionally Fractionated Boost for Localized High Risk Prostate Cancer</brief_title>
  <official_title>Randomized Trial of Concomitant Hypofractionated IMRT Boost Versus Conventional Fractionated IMRT Boost for Localized High Risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Patrick Cheung</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized trial comparing 2 external beam radiotherapy fractionation schemes in patients
      with localized high risk prostate cancer. Primary endpoint is acute toxicity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients enrolled onto this study will be randomized to one of the following treatment arms:

        -  Standard fractionation: Using 2 sequential IMRT plans, the pelvic lymph nodes and
           prostate will initially be treated to 46 Gy in 23 fractions, followed by a subsequent
           boost to the prostate to a total dose of 78 Gy.

        -  Hypofractionation: Using a one phase IMRT plan, the pelvic lymph nodes will be treated
           to a dose of 48 Gy in 25 fractions, while the prostate will be treated to a dose of 68
           Gy in 25 fractions concomitantly (simulataneous integrated boost).

      In addition, all patients receive 1.5- 3 years of androgen deprivation therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2011</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Toxicity</measure>
    <time_frame>within 3 months after starting radiotherapy</time_frame>
    <description>Proportion of patients experiencing grade &gt;=2 acute toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late Toxicity</measure>
    <time_frame>beyond 3 months of starting radiotherapy</time_frame>
    <description>Proportion of patients experiencing grade &gt;= 2 late toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical Control (Phoenix Definition)</measure>
    <time_frame>at 5 years</time_frame>
    <description>Actuarial measure of patients failing biochemically (defined as PSA nadir + 2 ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>at 5 years</time_frame>
    <description>Actuarial measure of patients being alive</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">178</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Standard Fractionation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Using 2 sequential IMRT plans, the pelvic lymph nodes and prostate will initially be treated to 46 Gy in 23 fractions, followed by a subsequent boost to the prostate to a total dose of 78 Gy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypofractionation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Using a one phase IMRT plan, the pelvic lymph nodes will be treated to a dose of 48 Gy in 25 fractions, while the prostate will be treated to a dose of 68 Gy in 25 fractions concomitantly (simulataneous integrated boost).</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Conventionally Fractionated versus Hypofractionated Boost</intervention_name>
    <arm_group_label>Standard Fractionation</arm_group_label>
    <arm_group_label>Hypofractionation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent obtained.

          -  Histologically confirmed diagnosis of adenocarcinoma of the prostate.

          -  T1-2 N0 M0, Gleason Score &lt;= 7, PSA 20 - 100

          -  T1-2 N0 M0, Gleason Score 8 - 10, PSA &lt;= 100

          -  T3 N0 M0, any Gleason Score, PSA &lt;= 100

        Exclusion Criteria:

          -  Patients with unilateral or bilateral hip replacement.

          -  Patients with active collagen vascular disease.

          -  Patients with active inflammatory bowel disease.

          -  Patients with previous radiotherapy to the pelvis.

          -  Patients with ataxia telangiectasia.

          -  Patients with nodal or distant metastases
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Cheung, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Toronto Sunnybrook Regional Cancer Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Deabreu</last_name>
    <phone>416-480-6100</phone>
    <phone_ext>1058</phone_ext>
    <email>andrea.deabreu@sunnybrook.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sunnybrook Odette Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Deabreu</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>1058</phone_ext>
      <email>andrea.deabreu@sunnybrook.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2018</study_first_submitted>
  <study_first_submitted_qc>May 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2018</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sunnybrook Health Sciences Centre</investigator_affiliation>
    <investigator_full_name>Dr. Patrick Cheung</investigator_full_name>
    <investigator_title>Radiation Oncologist</investigator_title>
  </responsible_party>
  <keyword>High Risk Prostate Cancer</keyword>
  <keyword>Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

